Search Records

The Airborne Radionuclide Concentrations (ARC) Dataset is a general dataset of airborne radionuclide concentrations analyzed at the Radiation Protection Bureau (RPB). The RPB is responsible for delivering Health Canada’s program in the area of ionizing radiation protection. This dataset includes...

Health Canada and the Canadian Advertising Preclearance Agencies (APAs) share the common goal of maintaining integrity in health product advertising. The purpose of this guidance document is to inform staff and stakeholders of the different roles these organizations play in achieving this goal.

This strategy document outlines the steps to be taken in order to optimize the use of RWE to improve the safety and effectiveness of medical devices across the product life cycle. As well, the plan describes the activities and the outputs required to achieve the objectives.

Health Canada’s commitments for an accessible and barrier-free Canada.

This report, which is tabled under section 20 of the Service Fees Act and section 4.2.8 of the Directive on Charging and Special Financial Authorities, contains information about the fees that Health Canada had the authority to charge in the 2022-23 fiscal year.

Evaluation reports The department periodically conducts evaluations of Global Affairs Canada priorities, programs and projects. Evaluation serves as a practical management tool for reviewing performance of programs and activities. The information gathered through an evaluation helps improve the...

Canada regularly inspects registrants that sell or distribute pest control products. These registrants are usually companies that own the pesticide registrations. Every year, PMRA inspect about 10% of companies. Inspections usually take 4 to 8 weeks; an additional 4 weeks may be needed if samples...

On April 28, 2016, Health Canada, the Australian Pesticides and Veterinary Medicines Authority (APVMA) and the New Zealand Ministry for Primary Industries (NZMPI) simultaneously approved a new use for pain relief in sheep for the veterinary drug Metacam.

This report, which is tabled under section 20 of the Service Fees Act and section 4.2.8 of the Directive on Charging and Special Financial Authorities, contains information about the fees that Health Canada had the authority to charge in the 2021-22 fiscal year.

Part of Health Canada’s work as a regulator is to engage and inform Canadians on issues about their health. Learn how we use consultations and other tools to help protect and improve the health of Canadians.